Cautionary Note on Forward-looking Statements

This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy, and the anticipated separation of the Company’s Consumer Health business. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; the Company’s ability to satisfy the necessary conditions to consummate the separation of the Company’s Consumer Health business on a timely basis or at all; the Company’s ability to successfully separate the Company’s Consumer Health business and realize the anticipated benefits from the separation; the New Consumer Health Company’s ability to succeed as a standalone publicly traded company; and risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the Company’s ability to execute business continuity plans, as a result of the COVID-19 pandemic. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this presentation speaks only as of the date of this presentation. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Cautionary Note on Non-GAAP Financial Measures

This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the Company’s website at www.investor.jnj.com/sales-earnings.cfm.
Environmental, Social & Governance strategy

Matt Orlando
Corporate Secretary and Worldwide Vice President, Corporate Governance
2021 Priority Topics Matrix

External Stakeholder Perspective
(Degree of stakeholder concern)

INCREASING IMPORTANCE

INCREASING IMPORTANCE

Johnson & Johnson Perspective
(Impact on business)

- Consumer health & patient safety
- Product quality
- Access
- Advancing public health
- Ethics & compliance
- Workforce safety & well-being
- R&D & innovation investment
- Anti-bribery & anti-corruption
- Cybersecurity & data privacy
- Workforce attraction, development & retention
- Animal rights & welfare
- Water management
- Sustainable products & packaging
- Digital innovation
- Strengthening health systems
- Supplier base transparency & integrity
- Community economic impact
- Biodiversity
- Climate change
- Human rights
- Diversity, equity & inclusion
- Ethos
- Environmental impact on human health
- Counterfeit & illicit trade

Johnson & Johnson
Our ESG Strategy

Our Credo

Our Purpose
We blend heart, science and ingenuity to profoundly change the trajectory of health for humanity.

ESG FOCUS AREAS

Champion global health equity
Empower our employees
Advance environmental health

Lead with accountability and innovation
Commitment to science and data-driven decision making, compliance, integrity and responsible business practices across the value chain.
Leading with accountability and innovation

98% of employees completed Code of Business Conduct training, the highest completion rate to date.
<table>
<thead>
<tr>
<th>Our Goals</th>
<th>U.N. Sustainable Development Goals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Champion global health equity</td>
<td>3</td>
</tr>
<tr>
<td>Global Access Plans</td>
<td></td>
</tr>
<tr>
<td>Access to HIV Treatment</td>
<td></td>
</tr>
<tr>
<td>Access to Tuberculosis Treatment</td>
<td></td>
</tr>
<tr>
<td>Developing Tuberculosis Treatment</td>
<td></td>
</tr>
<tr>
<td>Access to Schizophrenia Treatment</td>
<td></td>
</tr>
<tr>
<td>Women in Management</td>
<td></td>
</tr>
<tr>
<td>Ethnic/Racial Diversity in Management</td>
<td></td>
</tr>
<tr>
<td>Black/African Americans in Management</td>
<td></td>
</tr>
<tr>
<td>Healthiest Workforce Score</td>
<td></td>
</tr>
<tr>
<td>Women in STEM³D</td>
<td></td>
</tr>
<tr>
<td>Renewable Electricity</td>
<td></td>
</tr>
<tr>
<td>Carbon Neutrality for Our Operations</td>
<td></td>
</tr>
<tr>
<td>Scope 3 Emissions Reduction</td>
<td></td>
</tr>
<tr>
<td>Supplier Sustainability</td>
<td></td>
</tr>
<tr>
<td>Global Supplier Diversity and Inclusion</td>
<td></td>
</tr>
<tr>
<td>Partnerships for Good</td>
<td></td>
</tr>
</tbody>
</table>

**Our Health for Humanity 2025 Goals**
Johnson & Johnson’s disclosure continuum

### Mandatory Financial Reporting

- **2021 Annual Report**
- Annual Report/Form 10-K and Proxy Statement filed with SEC

### Voluntary or Mandatory ESG Reporting

- **Enterprise-level voluntary** Health for Humanity Report on progress in ESG priorities
- External repository of Enterprise policies and positions on a range of ESG topics
- Small number of policies or positions are posted to comply with local law (e.g., Tax Policy to comply with UK legislation)

### DEI publication:

- **You Belong: Diversity & Inclusive Impact Report**

### Other ESG Disclosures via surveys:

- **CDP Disclosure Insight Action**
- **FTSE4Good Index Series constituent.**

### Regulated by the SEC as informal corporate disclosure